Roivant Sciences Ltd (ROIV)

Jul 27, 2025

What is the dividend policy of Roivant Sciences Ltd. stockCapitalize on trading strategies that deliver - jammulinksnews.com

Jul 27, 2025

Jul 27, 2025

How volatile is Roivant Sciences Ltd. stock compared to the marketBuild a portfolio that outperforms the market - jammulinksnews.com

Jul 27, 2025

Jul 27, 2025

Published on: 2025-07-28 06:27:01 - jammulinksnews.com

Jul 27, 2025

Jul 27, 2025

What is the risk reward ratio of investing in Roivant Sciences Ltd. stockUnlock exclusive stock market forecasts - jammulinksnews.com

Jul 27, 2025

Jul 27, 2025

Does Roivant Sciences Ltd. stock perform well during market downturnsCapitalize on emerging trends for profits - jammulinksnews.com

Jul 27, 2025

Jul 25, 2025

Is Roivant Sciences Ltd. a good long term investmentUnbelievable profit margins - Autocar Professional

Jul 25, 2025

Jul 25, 2025

Roivant Sciences (ROIV) Anticipated to Benefit from Brepocitinib Developments | ROIV Stock News - GuruFocus

Jul 25, 2025

Jul 25, 2025

Goldman Sachs Resumes Roivant Sciences (ROIV) Coverage with ‘Buy’ Rating - MSN

Jul 25, 2025

Jul 25, 2025

Vivek Ramaswamy to welcome third child soon: Meet his wife and his two elder sons - The Times of India

Jul 25, 2025

Jul 24, 2025

Roivant Sciences Ltd. Stock Analysis and ForecastFree Stock Market Beginners Guide - Autocar Professional

Jul 24, 2025

Jul 23, 2025

Roivant Sciences’ president Venker sells $1.15 million in shares By Investing.com - Investing.com South Africa

Jul 23, 2025

Jul 23, 2025

Roivant Sciences’ president Venker sells $1.15 million in shares - Investing.com Australia

Jul 23, 2025

Jul 23, 2025

Roivant Sciences President Eric Venker Sells 100k Shares at $11.52, Buys 100k at $3.85. - AInvest

Jul 23, 2025

Jul 23, 2025

10 Best Biotech Stocks to Buy According to Billionaire Steve Cohen - Insider Monkey

Jul 23, 2025

Jul 23, 2025

What drives Roivant Sciences Ltd. stock priceExceptional risk-adjusted gains - jammulinksnews.com

Jul 23, 2025

Jul 23, 2025

What analysts say about Roivant Sciences Ltd. stockTriple-digit profit margins - jammulinksnews.com

Jul 23, 2025

Jul 18, 2025

(ROIV) Investment Analysis and Advice - news.stocktradersdaily.com

Jul 18, 2025

Jul 10, 2025

Goldman Sachs resumes Roivant Sciences stock coverage with Buy rating By Investing.com - Investing.com South Africa

Jul 10, 2025

Jul 10, 2025

Goldman Sachs resumes Roivant Sciences stock coverage with Buy rating - Investing.com India

Jul 10, 2025

Jul 07, 2025

How to Take Advantage of moves in (ROIV) - news.stocktradersdaily.com

Jul 07, 2025

Jul 05, 2025

Roivant Sciences: Booming Pipeline Without Product Revenues Creates Valuation Riddle - Seeking Alpha

Jul 05, 2025

Jun 26, 2025

'Just the beginning': Vivek Ramaswamy breaks record in raising fund for Guv election campaign, $8.5 milli - The Times of India

Jun 26, 2025

Jun 25, 2025

Hedge Fund and Insider Trading News: Ken Griffin, Warren Buffett, Michael Burry, AQR Capital Management, Tiger Global Management, Amplify Energy Corp (AMPY), Roivant Sciences ltd (ROIV), and More - Insider Monkey

Jun 25, 2025

Jun 24, 2025

Roivant Sciences Subsidiary Pulmovant Publishes Positive Phase 1 Data for Inhaled PH Treatment Mosliciguat - Yahoo Finance

Jun 24, 2025

Jun 23, 2025

Roivant Sciences (ROIV): Ramaswamy sells $13 million in shares - Investing.com

Jun 23, 2025

Jun 18, 2025

HC Wainwright & Co. Reiterates Buy Rating for Roivant Sciences (ROIV) | ROIV Stock News - GuruFocus

Jun 18, 2025

Jun 18, 2025

Cantor Fitzgerald reiterates overweight rating on Roivant Sciences stock By Investing.com - Investing.com India

Jun 18, 2025

Jun 18, 2025

H.C. Wainwright reiterates buy rating on Roivant Sciences stock By Investing.com - Investing.com India

Jun 18, 2025

Jun 18, 2025

Guggenheim maintains buy rating on Roivant Sciences stock amid DM study - Investing.com India

Jun 18, 2025

Jun 18, 2025

JPMorgan Maintains Positive Outlook on Roivant Sciences (ROIV) | ROIV Stock News - GuruFocus

Jun 18, 2025

Jun 17, 2025

Roivant (ROIV) Hosts Investor Webinar on Brepocitinib's Role in Dermatomyositis | ROIV Stock News - GuruFocus

Jun 17, 2025

Jun 16, 2025

Long Term Trading Analysis for (ROIV) - news.stocktradersdaily.com

Jun 16, 2025

Jun 16, 2025

Roivant (ROIV) Publishes Promising Phase 1 Results for Inhaled M - GuruFocus

Jun 16, 2025

Jun 10, 2025

Roivant Sciences at Goldman Sachs Conference: Strategic Execution Focus By Investing.com - Investing.com South Africa

Jun 10, 2025

Jun 10, 2025

Roivant Sciences at Goldman Sachs Conference: Strategic Execution Focus - Investing.com Australia

Jun 10, 2025

Jun 09, 2025

Roivant and Priovant to Host Investor Video Conference at 1:00 PM ET on Tuesday, June 17 on Brepocitinib and the Unmet Medical Need in Dermatomyositis - Yahoo Finance

Jun 09, 2025

Jun 09, 2025

Rare Disease Breakthrough: Roivant Reveals Brepocitinib Data for Dermatomyositis Treatment - Stock Titan

Jun 09, 2025